The mortality of chronic kidney disease in Chinese subjects: a 12-year cohort based on clinical data in electronic health record

中国人群慢性肾脏病死亡率:基于电子健康记录临床数据的12年队列研究

阅读:2

Abstract

BACKGROUND: Chronic kidney disease (CKD) is a global health problem with increasing prevalence. The objective of this study was to investigate the CKD mortality rate in a large cohort study based on electronic health record (EHR). METHODS: This was a retrospective cohort based on Hospital's EHR. The follow-up period was from January 2008 to December 2019. We used demographics, laboratory tests, comorbidities and mortality information to do the analysis. The mortality data was gained from the Chinese Center for Disease Control and Prevention (CDC) database. Then the data was analyzed in the whole participants and subgroups. RESULTS: 82,684 CKD patients were identified in final cohort. Overall, there were 10,454 patients who died during the 12-year follow-up. The crude mortality rate was 12.6% (2.4 per 100 patient-years). In CKD stages 4-5, the mortality rate significantly increased (10.2 and 8.8 per 100 patient-years, respectively). The major causes of death including cardiovascular diseases, infections and cancer. In the advanced (stages 4-5) CKD, the proportion of deaths caused by cancer significantly decreased (15-26% to 9-10%), while the proportion of deaths caused by renal failure markedly increased (2-4% to 10-21%). In the death group, patients with younger baseline age have a higher proportion of reaching ESRD before death: among patients with baseline age ≤35 years, for example, the percentage who died with ESKD was 28.8%, and the percentage of died with ESKD in patients with baseline age >80 years was only 14.9%. CONCLUSION: In conclusion, among the 82,684 CKD patients, the mortality rate was 2.4 per 100 patient-years. For advanced CKD patients, the mortality rate was significantly increased. As CKD progressed, deaths caused by cancer significantly decreased, while death caused by renal failure remarkably increased. Meanwhile, there may be a competing risk of all-cause mortality and progression to ESKD.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。